MaxCyte Stock Based Compensation vs Change In Cash Analysis

MXCT Stock  USD 4.34  0.09  2.03%   
MaxCyte financial indicator trend analysis is infinitely more than just investigating MaxCyte recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MaxCyte is a good investment. Please check the relationship between MaxCyte Stock Based Compensation and its Change In Cash accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.

Stock Based Compensation vs Change In Cash

Stock Based Compensation vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MaxCyte Stock Based Compensation account and Change In Cash. At this time, the significance of the direction appears to have weak relationship.
The correlation between MaxCyte's Stock Based Compensation and Change In Cash is 0.38. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Change In Cash in the same time period over historical financial statements of MaxCyte, assuming nothing else is changed. The correlation between historical values of MaxCyte's Stock Based Compensation and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of MaxCyte are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Stock Based Compensation i.e., MaxCyte's Stock Based Compensation and Change In Cash go up and down completely randomly.

Correlation Coefficient

0.38
Relationship DirectionPositive 
Relationship StrengthVery Weak

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Change In Cash

Most indicators from MaxCyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MaxCyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MaxCyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.At this time, MaxCyte's Selling General Administrative is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.76 in 2024, whereas Enterprise Value Multiple is likely to drop (10.89) in 2024.
 2021 2022 2023 2024 (projected)
Interest Expense1.0M126.9K145.9K138.6K
Depreciation And Amortization1.4M2.7M4.2M4.4M

MaxCyte fundamental ratios Correlations

0.830.930.861.00.930.83-0.64-0.92-0.40.810.820.450.980.80.90.840.90.950.910.99-0.380.790.950.830.99
0.830.940.750.810.960.66-0.42-0.95-0.360.70.940.260.730.680.750.990.970.870.970.75-0.340.680.750.960.85
0.930.940.880.920.950.83-0.62-0.99-0.370.830.90.330.870.780.860.950.980.910.990.88-0.420.830.870.90.92
0.860.750.880.860.790.95-0.64-0.89-0.260.760.650.260.860.870.960.780.80.840.860.87-0.450.960.940.680.81
1.00.810.920.860.910.83-0.64-0.9-0.40.80.80.470.990.790.890.810.880.940.890.99-0.370.780.950.810.99
0.930.960.950.790.910.71-0.46-0.95-0.490.710.940.440.850.720.840.950.980.930.960.86-0.30.70.860.970.94
0.830.660.830.950.830.71-0.57-0.81-0.20.680.510.20.860.930.90.710.70.830.80.87-0.590.940.880.570.75
-0.64-0.42-0.62-0.64-0.64-0.46-0.570.64-0.1-0.94-0.52-0.09-0.64-0.37-0.53-0.43-0.56-0.41-0.57-0.630.25-0.65-0.59-0.36-0.63
-0.92-0.95-0.99-0.89-0.9-0.95-0.810.640.32-0.84-0.9-0.29-0.84-0.77-0.87-0.95-0.98-0.89-0.99-0.860.36-0.84-0.87-0.89-0.91
-0.4-0.36-0.37-0.26-0.4-0.49-0.2-0.10.32-0.05-0.43-0.86-0.36-0.15-0.42-0.3-0.42-0.39-0.31-0.360.02-0.05-0.39-0.52-0.45
0.810.70.830.760.80.710.68-0.94-0.84-0.050.750.170.760.530.680.70.80.640.80.77-0.310.750.730.630.81
0.820.940.90.650.80.940.51-0.52-0.9-0.430.750.390.70.480.680.90.960.770.90.72-0.140.550.720.960.87
0.450.260.330.260.470.440.2-0.09-0.29-0.860.170.390.440.180.450.190.360.360.250.440.170.090.440.460.5
0.980.730.870.860.990.850.86-0.64-0.84-0.360.760.70.440.820.890.740.80.930.831.0-0.420.80.950.720.95
0.80.680.780.870.790.720.93-0.37-0.77-0.150.530.480.180.820.870.740.680.870.780.83-0.470.90.840.60.7
0.90.750.860.960.890.840.9-0.53-0.87-0.420.680.680.450.890.870.760.810.890.840.9-0.30.870.970.730.85
0.840.990.950.780.810.950.71-0.43-0.95-0.30.70.90.190.740.740.760.960.890.980.77-0.40.740.770.930.83
0.90.970.980.80.880.980.7-0.56-0.98-0.420.80.960.360.80.680.810.960.870.980.82-0.290.730.820.950.91
0.950.870.910.840.940.930.83-0.41-0.89-0.390.640.770.360.930.870.890.890.870.910.94-0.430.770.920.850.92
0.910.970.990.860.890.960.8-0.57-0.99-0.310.80.90.250.830.780.840.980.980.910.85-0.430.820.840.910.9
0.990.750.880.870.990.860.87-0.63-0.86-0.360.770.720.441.00.830.90.770.820.940.85-0.420.810.960.740.96
-0.38-0.34-0.42-0.45-0.37-0.3-0.590.250.360.02-0.31-0.140.17-0.42-0.47-0.3-0.4-0.29-0.43-0.43-0.42-0.5-0.34-0.22-0.3
0.790.680.830.960.780.70.94-0.65-0.84-0.050.750.550.090.80.90.870.740.730.770.820.81-0.50.850.580.71
0.950.750.870.940.950.860.88-0.59-0.87-0.390.730.720.440.950.840.970.770.820.920.840.96-0.340.850.740.92
0.830.960.90.680.810.970.57-0.36-0.89-0.520.630.960.460.720.60.730.930.950.850.910.74-0.220.580.740.86
0.990.850.920.810.990.940.75-0.63-0.91-0.450.810.870.50.950.70.850.830.910.920.90.96-0.30.710.920.86
Click cells to compare fundamentals

MaxCyte Account Relationship Matchups

MaxCyte fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets30.0M51.8M284.1M286.7M268.3M281.7M
Short Long Term Debt Total7.2M7.0M5.7M16.1M18.7M19.7M
Other Current Liab3.6M5.2M6.5M8.3M9.7M10.2M
Total Current Liabilities9.3M11.6M15.6M15.4M17.9M9.7M
Total Stockholder Equity13.6M33.2M262.9M254.0M232.2M243.8M
Property Plant And Equipment Net5.5M6.5M13.4M33.6M34.8M36.5M
Current Deferred Revenue3.2M4.8M6.7M6.7M5.1M3.5M
Net Debt(8.0M)(11.8M)(42.1M)5.0M(27.8M)(26.4M)
Retained Earnings(83.4M)(95.2M)(114.3M)(137.9M)(175.8M)(167.0M)
Accounts Payable2.1M890.2K1.8M292K743K705.9K
Cash15.2M18.8M47.8M11.1M46.5M48.8M
Non Current Assets Total5.5M6.5M13.7M34.4M78.1M82.0M
Cash And Short Term Investments16.7M34.8M255.0M227.3M168.3M176.7M
Net Receivables3.2M5.2M6.9M11.2M5.8M4.3M
Common Stock Shares Outstanding56.4M69.5M90.6M101.7M103.3M66.8M
Liabilities And Stockholders Equity30.0M51.8M284.1M286.7M268.3M281.7M
Non Current Liabilities Total7.0M6.9M5.6M17.3M18.3M19.2M
Inventory3.7M4.3M5.2M8.6M12.2M12.8M
Other Current Assets797.1K1.0M3.3M6.0M3.9M4.1M
Total Liab16.4M18.6M21.2M32.7M36.1M37.9M
Total Current Assets24.5M45.3M270.4M252.3M190.2M199.7M
Short Term Debt508.9K672.6K527.2K157K1.5M845.8K
Common Stock574K773.8K1.0M1.0M1.0M542.8K
Other Stockholder Equity96.4M127.7M376.2M390.8M406.9M222.4M
Other Liab338.1K646.6K450.2K1.3M1.5M1.6M
Net Tangible Assets13.6M33.2M262.9M254.0M292.1M306.7M
Common Stock Total Equity574K773.8K1.0M1.0M1.2M807.8K
Capital Lease Obligations2.3M2.0M5.7M16.1M18.7M19.7M
Net Invested Capital18.5M38.1M262.9M254.0M232.2M133.2M
Property Plant And Equipment Gross5.5M6.5M7.7M23.7M45.0M47.3M
Non Current Liabilities Other338.1K646.6K450.2K1.3M283K268.9K
Net Working Capital15.1M33.6M254.8M236.8M172.3M118.2M
Property Plant Equipment5.5M6.5M13.4M23.7M27.3M28.6M
Short Term Investments1.5M16.0M207.3M216.3M121.8M103.8M
Capital Stock574K773.8K1.0M1.0M1.0M905.1K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.